# 2025 Egyptian guidelines for the management of dyslipidemia

## TL;DR

The 2025 Egyptian guidelines aim to better manage dyslipidemia by tailoring recommendations to the local population and emphasizing early detection and lifestyle changes.

## Contribution

The guidelines introduce a novel 'extreme-risk' category and a context-specific framework for dyslipidemia management in Egypt.

## Key findings

- A structured consensus process was used to develop the guidelines involving cardiologists and endocrinologists.
- The guidelines prioritize lifestyle interventions and introduce intensified strategies for high-risk patients.
- The framework aims to reduce cardiovascular risk and improve outcomes in the Egyptian population.

## Abstract

The burden of premature atherosclerotic cardiovascular disease (ASCVD) in Egypt remains disproportionately high, and current international dyslipidemia guidelines have proven insufficient in achieving target lipid levels in the local population. This underscores the necessity for a context-specific national guideline. The 2025 Egyptian Guidelines for the Management of Dyslipidemia were developed through a structured consensus process led by an expert panel of cardiologists, endocrinologists, and representatives from national medical societies.

The methodology included two rounds of blind voting followed by a consensus meeting to ensure rigorous evaluation. The guidelines emphasize the importance of early detection of dyslipidemia through systematic screening programs and prioritize lifestyle interventions as the cornerstone of management. A novel “extreme-risk” category was introduced to identify patients requiring intensified lipid-lowering strategies, including early initiation of combination pharmacotherapy. Additionally, the recommendations highlight the critical role of ongoing monitoring and follow-up to sustain long-term lipid control and reduce cardiovascular risk.

The current guidelines provide a simplified, yet evidence-based framework tailored to the Egyptian population, aiming to optimize dyslipidemia management, reduce ASCVD-related complications, and improve overall cardiovascular outcomes.

The online version contains supplementary material available at 10.1186/s43044-026-00716-9.